Aptose Biosciences Inc (APTO) Receives Consensus Recommendation of “Hold” from Analysts
Shares of Aptose Biosciences Inc (NASDAQ:APTO) (TSE:APS) have earned a consensus recommendation of “Hold” from the six research firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have given a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $6.00.
APTO has been the subject of a number of recent research reports. Roth Capital reiterated a “buy” rating and set a $5.00 price target on shares of Aptose Biosciences in a report on Monday, October 23rd. ValuEngine downgraded shares of Aptose Biosciences from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Zacks Investment Research upgraded shares of Aptose Biosciences from a “sell” rating to a “hold” rating in a report on Monday, December 25th. HC Wainwright reiterated a “buy” rating and set a $6.00 price target (up from $4.00) on shares of Aptose Biosciences in a report on Wednesday, December 13th. Finally, Canaccord Genuity set a $7.00 target price on shares of Aptose Biosciences and gave the company a “buy” rating in a report on Wednesday, November 15th.
A hedge fund recently raised its stake in Aptose Biosciences stock. Acadian Asset Management LLC boosted its stake in Aptose Biosciences Inc (NASDAQ:APTO) (TSE:APS) by 316.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 44,421 shares of the biotechnology company’s stock after purchasing an additional 33,766 shares during the quarter. Acadian Asset Management LLC owned about 0.17% of Aptose Biosciences worth $100,000 as of its most recent filing with the SEC. 0.92% of the stock is owned by institutional investors.
Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last issued its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. analysts expect that Aptose Biosciences will post -0.61 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece of content was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/02/14/aptose-biosciences-inc-apto-receives-consensus-recommendation-of-hold-from-analysts.html.
About Aptose Biosciences
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.